"Occult" bilingualism in children with school problems.

D. Mccormick

DOI: https://doi.org/10.1111/J.1746-1561.1980.TB03900.X

1980-02-01

Journal of School Health

Abstract:

What problem does this paper attempt to address?

Prognostication of Survival Outcomes in Patients Diagnosed with Glioblastoma.

Damir Nizamutdinov,Eileen M. Stock,Jad A. Dandashi,Eliana A. Vasquez,Ying Mao,Samantha Dayawansa,Jun Zhang,Erxi Wu,Ekokobe Fonkem,Jason H. Huang

DOI: https://doi.org/10.1016/j.wneu.2017.09.104

IF: 2.21

2017-01-01

World Neurosurgery

Abstract:OBJECTIVE: Glioblastoma multiforme (GBM) is an aggressive primary brain tumor with dismal survival. This study aims to examine the prognostic value of primary tumor sites and race on survival outcomes. METHODS: Patient data obtained from the Scott and White Hospital Brain Tumor Registry (1976-2013) were stratified according to sex, age, race, primary tumor site, vital status, and survival. RESULTS: Of the 645 patients, 580 (89.9%) were diagnosed with GBM not otherwise specified (GBM NOS), 57 (8.8%) with GBM, and 8 (1.2%) with giant-cell GBM. Most were male (53.5%), aged 50 years or older (78.7%). The white population had the highest GBM prevalence (87.1%) and the lowest overall survival versus all other race groups (6.6% vs. 30.1%; P < 0.01). The black population had a relatively low prevalence of GBM (5.9%) and the greatest overall survival versus all others (47.4% vs. 7.3%; P < 0.01). Primary tumor sites located in the temporal (25.8% vs. 20.2%; P=0.03), occipital (8.1% vs. 2.9%; P=0.05), and parietal lobes (24.2% vs. 20.8%; P=0.05) had a greater occurrence in surviving individuals. The overall survival for men versus women was (62.9% vs. 37.1%; P=0.12). CONCLUSIONS: Black racial background and temporal, occipital, or parietal primary tumor sites are suggestive of positive survival outcomes. Conversely, white racial background with primary tumor sites in the brain overlapping and NOS areas seem to be associated with negative outcomes and decreased survival. Thus, racial background and primary tumor site may be useful prognostic factors in patients with GBM.
Long-term survival of patients with glioblastoma multiforme (GBM)

Nicolas R. Smoll,Karl Schaller,Oliver P. Gautschi

DOI: https://doi.org/10.1016/j.jocn.2012.05.040

IF: 2.116

2013-05-01

Journal of Clinical Neuroscience

Abstract:Long-term survival is an often used, yet poorly defined, concept in the study of glioblastoma multiforme (GBM). This study suggests a method to define a time-point for long-term survival in patients with GBM. Data for this study were obtained from the Surveillance, Epidemiology and End-Results database, which was limited to the most recent data using the period approach. Relative survival measures were used and modelled using piecewise constant hazards to describe the survival profile of long-term survivors of GBM. For patients with GBM, the first quarter of the second year (5th quarter) post-diagnosis is considered to be the peak incidence of mortality with an excess hazard ratio of 7.58 (95% confidence interval=6.54, 8.78) and the risk of death due to GBM decreases to half of its rate at 2.5 years post-diagnosis. The 2.5-year cumulative relative survival (CRS) for all patients is approximately 8%, with a CRS of approximately 2% at 10 years. Using the definition of long-term survival suggested here, the results indicate that long-term survivors are patients who survive at least 2.5 years post-diagnosis. The most likely time period for patients with GBM to die is the 5th quarter post-diagnosis.

neurosciences,clinical neurology
Epidemiologic Features, Survival, and Prognostic Factors Among Patients With Different Histologic Variants of Glioblastoma: Analysis of a Nationwide Database

Li-Tsun Shieh,Chung-Han Ho,How-Ran Guo,Chien-Cheng Huang,Yi-Chia Ho,Sheng-Yow Ho

DOI: https://doi.org/10.3389/fneur.2021.659921

IF: 3.4

2021-11-24

Frontiers in Neurology

Abstract:Background: Glioblastoma (GBM) is the most common primary intracranial malignancy. Previous studies found incidence of GBM varies substantially by age, sex, race and ethnicity, and survival also varies by country, ethnicity, and treatment. Gliosarcoma (GSM) and giant cell glioblastoma (GC-GBM) are different histologic variants of GBM with distinct clinico-pathologic entities. We conducted a study to compare epidemiology, survival, and prognostic factors among the three. Methods: We identified GBM patients diagnosed between 2000 and 2016 using the Taiwan Cancer Registry and followed them using the death registry. Survival was compared among conventional GBM and two histologic variants. The potential confounding factors evaluated in this study included registered year, age, sex, and treatment modality (resection, radiotherapy, and chemotherapy). Results: We enrolled 3,895 patients, including 3,732 (95.8%) with conventional GBM, 102 (2.6%) with GSM, and 61 (1.6%) with GC-GBM. GC-GBM patients had younger mean age at diagnosis (49.5 years) than conventional GBM patients (58.7 years) and GSM patients (61.3 years) ( p < 0.01). The three groups had similar sex distributions ( p = 0.29). GC-GBM had a longer median survival [18.5, 95% confidence interval (CI): 15.8–25.3 months] than conventional GBM (12.5, 95%CI: 12.0–13.0 months) and GSM (12.8, 95%CI: 9.2–16.2 months), and the differences in overall survival did not attain statistical significance ( p = 0.08, log-rank test). In univariate analysis, GC-GBM had better survival than conventional GBM, but the hazard ratio (0.91) did not reach statistical significance (95%CI: 0.69–1.20) in the multivariate analysis. Young ages (≤ 40 years), female sex, resection, radiotherapy, and chemotherapy were factors associated with better survival in overall GBMs. In subtype analyses, these factors remained statistically significant for conventional GBM, as well as radiotherapy for GSM. Conclusion: Our analysis found conventional GBM and its variants shared similar poor survival. Factors with age ≤ 40 years, female sex, resection, radiotherapy, and chemotherapy were associated with better prognosis in conventional GBM patients.

neurosciences,clinical neurology
Prognosis of glioblastoma patients improves significantly over time interrogating historical controls

A Thomas-Joulié,S Tran,L El Houari,A Seyve,F Bielle,C Birzu,F Lozano-Sanchez,K Mokhtari,M Giry,Y Marie,F Laigle-Donadey,C Dehais,C Houillier,D Psimaras,A Alentorn,A Laurenge,M Touat,M Sanson,K Hoang-Xuan,A Kas,L Rozenblum,M-O Habert,L Nichelli,D Leclercq,D Galanaud,J Jacob,C Karachi,L Capelle,A Carpentier,B Mathon,L Belin,A Idbaih,A. Thomas-Joulié,S. Tran,L. El Houari,A. Seyve,F. Bielle,C. Birzu,F. Lozano-Sanchez,K. Mokhtari,M. Giry,Y. Marie,F. Laigle-Donadey,C. Dehais,C. Houillier,D. Psimaras,A. Alentorn,A. Laurenge,M. Touat,M. Sanson,K. Hoang-Xuan,A. Kas,L. Rozenblum,M.-O. Habert,L. Nichelli,D. Leclercq,D. Galanaud,J. Jacob,C. Karachi,L. Capelle,A. Carpentier,B. Mathon,L. Belin,A. Idbaih

DOI: https://doi.org/10.1016/j.ejca.2024.114004

IF: 10.002

2024-05-01

European Journal of Cancer

Abstract:BACKGROUND: Glioblastoma (GBM) is the most common devastating primary brain cancer in adults. In our clinical practice, median overall survival (mOS) of GBM patients seems increasing over time.METHODS: To address this observation, we have retrospectively analyzed the prognosis of 722 newly diagnosed GBM patients, aged below 70, in good clinical conditions (i.e. Karnofsky Performance Status -KPS- above 70%) and treated in our department according to the standard of care (SOC) between 2005 and 2018. Patients were divided into two groups according to the year of diagnosis (group 1: from 2005 to 2012; group 2: from 2013 to 2018).RESULTS: Characteristics of patients and tumors of both groups were very similar regarding confounding factors (age, KPS, MGMT promoter methylation status and treatments). Follow-up time was fixed at 24 months to ensure comparable survival times between both groups. Group 1 patients had a mOS of 19 months ([17.3-21.3]) while mOS of group 2 patients was not reached. The recent period of diagnosis was significantly associated with a longer mOS in univariate analysis (HR=0.64, 95% CI [0.51 - 0.81]), p < 0.001). Multivariate Cox analysis showed that the period of diagnosis remained significantly prognostic after adjustment on confounding factors (adjusted Hazard Ratio (aHR) 0.49, 95% CI [0.36-0.67], p < 0.001).CONCLUSION: This increase of mOS over time in newly diagnosed GBM patients could be explained by better management of potentially associated non-neurological diseases, optimization of validated SOC, better management of treatments side effects, supportive care and participation in clinical trials.

oncology
EPID-34. GEODEMOGRAPHIC CLASSIFICATION OF GLIOBLASTOMA RISK IN A RURAL HOSPITAL SYSTEM: RELATIONSHIP TO TUMOR INCIDENCE AND OVERALL SURVIVAL

Ali Haadi,Justin Kosman,Shane Bross,Jesse Manikowski,Bradley Hinger,Andrew Conger,Joseph Vadakara,Na Tosha Gatson

DOI: https://doi.org/10.1093/neuonc/noz175.334

2019-11-01

Abstract:Abstract In 2019, a projected 86,000 persons in the US will be diagnosed with a primary brain tumor, with an estimated prevalence of 700,000. Glioblastoma (GBM) is the deadliest and most common of these tumors in adults with an overall survival ~15 months. Exposure to ionizing radiation is the single known environmental risk factor for GBM. Most research in the field is directed at treatment and tumor biology/classification. There is growing interest in geodemographics, disease prevention, and measuring quality-survival in GBM. We evaluated 622 GBM patients (2006 to 2018) in Northeastern/Northcentral Pennsylvania treated at one of the nation’s largest rural hospital systems. Each patient was geocoded (plotted longitude/latitude) address at time of diagnosis and we used medical records, projected 2015 Census, and Environmental Protection Agency data to develop risk maps. Preliminary evaluation of overall survival (OS) and incidence related to distance from hospital, age, sex, level of education, insurance, income, and income disparity (Gini coefficient measure of income inequality) was completed. Interestingly, all significant clusters of high GBM incidence lay along water-ways or overlapped with high coal mine reprocessing. Contrary to recent studies, there was no significant sex or distance (0mi to 150mi) impact on survival. However, each age-decile increase resulted in an average 9mo decrease in OS (37mo[ 71yo]). Counties with the lowest OS shared geodemographic characteristics such as fewer insured and lower incomes (low income inequality), and counties with more college educated persons had longer survival. Counties with higher GBM incidences had better insured percentages, lower incomes (high income inequality), and large polarity between high school uneducated and college educated persons. Rural populations potentially demonstrate unique geodemographic characteristics that might better predict disease outcomes. Studies in this area could influence improvements in public policy and prevention-focused health literacy opportunities.

oncology,clinical neurology
Radt-38. Clinical, Molecular And Imaging Features Associated With Long Term Survival In Glioblastoma Patients

Muhammad Sharif,Carrie Andrews,Sophia Shah,Nilanjan Haldar,Louis Cappelli,Tingting Zhan,Iyad Alnahhas,Wenyin Shi

DOI: https://doi.org/10.1093/neuonc/noae165.0322

2024-11-29

Neuro-Oncology

Abstract:INTRODUCTIONGlioblastoma (GBM) is the most common malignant brain tumor in adults and has poor prognosis despite standard of care treatment. Nevertheless, certain patients surpass survival expectations. This study seeks to identify the clinical, molecular, and imaging characteristics of GBM associated with extended patient survival. METHODSIn this retrospective cohort study, we examined records of adult GBM patients (WHO 2016 classification) treated at Thomas Jefferson University Hospital from 2010 to 2023. Exclusion criteria included a preoperative Karnofsky Performance Status (KPS) below 60 and treatment with hypo-fractionated radiation therapy. Patients were categorized into two groups: short-term survivors (STS), who survived less than 36 months from diagnosis, and long-term survivors (LTS), who survived more than 36 months. We reviewed patient charts and pathology reports for comprehensive clinical and molecular data. For radiomics analysis, tumor segmentation was performed using CaPTk software on the initial diagnostic MRI (T1 pre and post-contrast, FLAIR and T2 sequences). The relationship between overall survival of more than three years was analyzed with univariable logistic models for potential predictors using R statistical software. RESULTSOf the cohort of 210 patients, 37 (17.6%) survived beyond three years. The median age at diagnosis was 55 years (range; 29-79) Twenty-two patients were male and 15 were female. Twenty-two percent had IDH mutation and 65% had MGMT methylation. Factors associated with long-term survival included younger age at diagnosis (p =0.007), MGMT hypermethylation (p =0.019), IDH mutation (p=0.001), absence of TERT mutation (p = 0.002), higher average number of adjuvant temozolomide cycles (10 vs. 5; p = 0.005), and smaller volume of enhancing tumor on T1 post-contrast imaging segmentation (p=0.022). But there was no significant difference in FLAIR abnormality or necrotic core volumes between the groups. CONCLUSIONIn our cohort of GBM patients, patients diagnosed at a younger age, MGMT hypermethylation, IDH mutation, absence of TERT mutation, receiving more cycles of adjuvant temozolomide treatment, and smaller enhancing tumor volume on preoperative T1 post-contrast imaging were associated with longer survival. Future research involving larger cohorts and validation of our findings is needed.

oncology,clinical neurology
Epid-28. Trends In Low Grade Glioma Prognosis And The Evolving Impact Of Gross Total Resection Across Fifty Years: A Multicohort Analysis

Michael Jin,Jacob Young,Gray Umbach,Karthik Ravi,Michael Lim,Shawn Hervey-Jumper

DOI: https://doi.org/10.1093/neuonc/noae165.0564

2024-11-29

Neuro-Oncology

Abstract:Significant advancements in neurosurgical planning, approach, and practice over the past five decades have improved the surgical management of diffuse low and high-grade gliomas. We sought to evaluate the extent to which LGG survival outcomes have evolved over the past fifty years using glioma registry datasets with histopathological groups defined by WHO diagnostic criteria and supplemented with next generation genome-sequencing. Three datasets (SEER, TCGA, and GENIE) were used to evaluate trends in prognosis following LGG diagnosis and resection between 1975 and present (GBM as a comparator cohort). The primary outcomes evaluated were longitudinal disease-specific survival and overall survival, with secondary fixed-timepoint outcomes evaluated at 12-months, 24-months, and 60-months. Subjects from SEER were categorized by histology, while subjects from TCGA and GENIE were included based IDH mutation status with available histopathology. A total of 39,958 adult patients were included. Overall survival increased for both LGG and GBM between 1975 and 2010, however only LGG outcomes continued to improve following 2010 (2010-; HR=0.955, 95%CI 0.926 to 0.986). Evaluation of the interaction between resection extent and diagnosis year revealed a progressive increase in the survival benefit of GTR in recent years, particularly for LGG. Independent of other available clinical/molecular features and considering the interaction term between year of diagnosis and resection extent, the gap in independent prognostic benefit associated with GTR between LGG and GBM has significantly widened (2010-2020 vs 1990-2000, p <0.05). Over the past three decades, consistent improvements in LGG outcomes were observed while prognosis following GBM diagnosis has remained largely unchanged following 2010. Notably, we observed increasing prognostic value of achieving GTR particularly in patients with LGG.

oncology,clinical neurology
Multiparametric Radiogenomic Model to Predict Survival in Patients with Glioblastoma

Keon Mahmoudi,Daniel H. Kim,Elham Tavakkol,Shingo Kihira,Adam Bauer,Nadejda Tsankova,Fahad Khan,Adilia Hormigo,Vivek Yedavalli,Kambiz Nael

DOI: https://doi.org/10.3390/cancers16030589

2024-01-30

Cancers

Abstract:Background: Clinical, histopathological, and imaging variables have been associated with prognosis in patients with glioblastoma (GBM). We aimed to develop a multiparametric radiogenomic model incorporating MRI texture features, demographic data, and histopathological tumor biomarkers to predict prognosis in patients with GBM. Methods: In this retrospective study, patients were included if they had confirmed diagnosis of GBM with histopathological biomarkers and pre-operative MRI. Tumor segmentation was performed, and texture features were extracted to develop a predictive radiomic model of survival (<18 months vs. ≥18 months) using multivariate analysis and Least Absolute Shrinkage and Selection Operator (LASSO) regularization to reduce the risk of overfitting. This radiomic model in combination with clinical and histopathological data was inserted into a backward stepwise logistic regression model to assess survival. The diagnostic performance of this model was reported for the training and external validation sets. Results: A total of 116 patients were included for model development and 40 patients for external testing validation. The diagnostic performance (AUC/sensitivity/specificity) of the radiomic model generated from seven texture features in determination of ≥18 months survival was 0.71/69.0/70.3. Three variables remained as independent predictors of survival, including radiomics (p = 0.004), age (p = 0.039), and MGMT status (p = 0.025). This model yielded diagnostic performance (AUC/sensitivity/specificity) of 0.77/81.0/66.0 (training) and 0.89/100/78.6 (testing) in determination of survival ≥ 18 months. Conclusions: Results show that our radiogenomic model generated from radiomic features at baseline MRI, age, and MGMT status can predict survival ≥ 18 months in patients with GBM.

oncology
Nimg-59. Comparative Analysis Of Long-Term Glioblastoma Survivors Using Machine Learning Generated Radio-Pathomic Metrics

Daniel Aaronson,Samuel Bobholz,Savannah Duenweg,Fitzgerald Kyereme,Allison Lowman,Biprojit Nath,Aleksandra Winiarz,Jennifer Connelly,E Kelly Mrachek,Max Krucoff,Anjishnu Banerjee,Peter LaViolette

DOI: https://doi.org/10.1093/neuonc/noae165.0823

2024-11-29

Neuro-Oncology

Abstract:BACKGROUNDGlioblastoma (GBM) remains the most devastating central nervous system malignancy with poor overall survival (OS), even with gross total resection (GTR) and chemoradiation. Identifying factors associated with long-term survival (LTS) in GBM patients is challenging but crucial for improving prognostic models. This study compares an internal dataset of the top 10% long-term survivors of GBM (n=14) against a combined external cohort of 528 GBM patients who underwent GTR. METHODSWe used a previously published machine learning-generated radio-pathomic model based on autopsy tissue as ground-truth to generate whole-brain maps of cell density and tumor probability maps (TPM) using conventional preoperative MRI sequences in both our internal dataset and a combined external cohort of GBM patients who underwent GTR from the UCSF-PDGM-v2 and UPenn-GBM databases. We then analyzed clinical and radio-pathomic metrics, including cell density and TPM values within contrast-enhancing (CE) and FLAIR hyperintense regions. Statistical comparisons were performed using t-tests. RESULTSCell density metrics showed significant differences, with lower cell density in contrast-enhancing regions (t-value: 4.709, p<0.001; median: 1559 vs. 1959) and in FLAIR hyperintense regions (t-value: 3.585, p<0.001; median: 1356 vs. 1568) within the LTS group. TPM metrics also showed significant differences, with lower TPM values in contrast-enhancing regions (t-value: 3.312, p<0.001; median: 0.71 vs. 0.72) and in non-enhancing regions (t-value: 2.606, p<0.01; median: 0.68 vs. 0.69) in the LTS group. CONCLUSIONOur comparative analysis reveals distinct radio-pathomic characteristics associated with long-term survival in GBM patients. Reduced cell density and lower TPM values in both contrast-enhancing and FLAIR hyperintense regions are significantly correlated with long-term survival. These findings suggest that integrating radio-pathomic data may enhance prognostic models and warrants further studies evaluating the relationship of these markers and OS.

oncology,clinical neurology
Natural Course and Prognosis of Primary Spinal Glioblastoma: A Nationwide Study

Aymeric Amelot,Louis-Marie Terrier,Bertrand Mathon,Christophe Joubert,Thiebaud Picart,Vincent Jecko,Luc Bauchet,Florian Bernard,Xavier Castel,Louis Chenin,Ann-Rose Cook,Evelyne Emery,Dominique Figarella-Branger,Guillaume Gauchotte,Thomas Graillon,Anne Jouvet,Michel Kalamarides,Steven Knafo,Arnaud Lazard,Vincent Lubrano,Karima Mokhtari,Valérie Rigau,Vincent Roualdes,Audrey Rousseau,Romuald Seizeur,Emmanuelle Uro-Coste,Jimmy Voirin,Philippe Metellus,Johan Pallud,Ilyess Zemmoura,Medullary Glioblastoma study group

DOI: https://doi.org/10.1212/WNL.0000000000206834

IF: 9.9

2023-04-04

Neurology

Abstract:Background and objectives: Primary spinal glioblastoma (PsGBM) is extremely rare. The dramatic neurologic deterioration and unresectability of PsGBM makes it a particularly disabling malignant neoplasm. Because it is a rare and heterogeneous disease, the assessment of prognostic factors remains limited. Methods: PsGBMs were identified from the French Brain Tumor Database and the Club de Neuro-Oncologie of the Société Française de Neurochirurgie retrospectively. Inclusion criteria were age 18 years or older at diagnosis, spinal location, histopathologic diagnosis of newly glioblastoma according to the 2016 World Health Organization classification, and surgical management between 2004 and 2016. Diagnosis was confirmed by a centralized neuropathologic review. The primary outcome was overall survival (OS). Therapeutic interventions and neurologic outcomes were also collected. Results: Thirty-three patients with a histopathologically confirmed PsGBM (median age 50.9 years) were included (27 centers). The median OS was 13.1 months (range 2.5-23.7), and the median progression-free survival was 5.9 months (range 1.6-10.2). In multivariable analyses using Cox model, Eastern Cooperative Oncology Group (ECOG) performance status at 0-1 was the only independent predictor of longer OS (hazard ratio [HR] 0.13, 95% CI 0.02-0.801; p = 0.02), whereas a Karnofsky performance status (KPS) score <60 (HR 2.89, 95% CI 1.05-7.92; p = 0.03) and a cervical anatomical location (HR 4.14, 95% CI 1.32-12.98; p = 0.01) were independent predictors of shorter OS. The ambulatory status (Frankel D-E) (HR 0.38, 95% CI 0.07-1.985; p = 0.250) was not an independent prognostic factor, while the concomitant standard radiochemotherapy with temozolomide (Stupp protocol) (HR 0.35, 95% CI 0.118-1.05; p = 0.06) was at the limit of significance. Discussion: Preoperative ECOG performance status, KPS score, and the location are independent predictors of OS of PsGBMs in adults. Further analyses are required to capture the survival benefit of concomitant standard radiochemotherapy with temozolomide.
Whole-Genome Multi-omic Study of Survival in Patients with Glioblastoma Multiforme

Yeni L Bernal Rubio,Agustin González-Reymúndez,Kuan-Han H Wu,Corinne E Griguer,Juan P Steibel,Gustavo de Los Campos,Andrea Doseff,Kathleen Gallo,Ana I Vazquez

DOI: https://doi.org/10.1534/g3.118.200391

2018-11-06

Abstract:Glioblastoma multiforme (GBM) has been recognized as the most lethal type of malignant brain tumor. Despite efforts of the medical and research community, patients' survival remains extremely low. Multi-omic profiles (including DNA sequence, methylation and gene expression) provide rich information about the tumor. These profiles are likely to reveal processes that may be predictive of patient survival. However, the integration of multi-omic profiles, which are high dimensional and heterogeneous in nature, poses great challenges. The goal of this work was to develop models for prediction of survival of GBM patients that can integrate clinical information and multi-omic profiles, using multi-layered Bayesian regressions. We apply the methodology to data from GBM patients from The Cancer Genome Atlas (TCGA, n = 501) to evaluate whether integrating multi-omic profiles (SNP-genotypes, methylation, copy number variants and gene expression) with clinical information (demographics as well as treatments) leads to an improved ability to predict patient survival. The proposed Bayesian models were used to estimate the proportion of variance explained by clinical covariates and omics and to evaluate prediction accuracy in cross validation (using the area under the Receiver Operating Characteristic curve, AUC). Among clinical and demographic covariates, age (AUC = 0.664) and the use of temozolomide (AUC = 0.606) were the most predictive of survival. Among omics, methylation (AUC = 0.623) and gene expression (AUC = 0.593) were more predictive than either SNP (AUC = 0.539) or CNV (AUC = 0.547). While there was a clear association between age and methylation, the integration of age, the use of temozolomide, and either gene expression or methylation led to a substantial increase in AUC in cross-validaton (AUC = 0.718). Finally, among the genes whose methylation was higher in aging brains, we observed a higher enrichment of these genes being also differentially methylated in cancer.
Long-term survivors in 976 supratentorial glioblastoma, IDH-wildtype patients

Oumaima Aboubakr,Alessandro Moiraghi,Angela Elia,Arnault Tauziede-Espariat,Alexandre Roux,Arthur Leclerc,Martin Planet,Aziz Bedioui,Giorgia Antonia Simboli,Frédéric Dhermain,Eduardo Parraga,Chiara Benevello,Houssem Fathallah,Jun Muto,Fabrice Chrétien,Edouard Dezamis,Catherine Oppenheim,Pascale Varlet,Marc Zanello,Johan Pallud

DOI: https://doi.org/10.3171/2024.5.JNS24393

2024-08-30

Abstract:Objective: Glioblastoma, isocitrate dehydrogenase (IDH)-wildtype is the most aggressive glioma with poor outcomes. The authors explored survival rates and factors associated with long-term survival in patients harboring a glioblastoma, IDH-wildtype. Methods: In an observational, retrospective, single-center study, the authors examined the medical records of 976 adults newly diagnosed with supratentorial glioblastomas, IDH-wildtype between January 2000 and January 2021. They analyzed clinical-, imaging-, and treatment-related factors associated with 2-year and 5-year survival. Results: The median overall survival was 11.2 months (12.2 months for patients included after 2005 and the introduction of standard combined chemoradiotherapy). The median progression-free survival was 9.4 months (10.0 months for patients included after 2005). Overall, 17.6% of patients reached a 2-year overall survival, while 2.2% of patients reached a 5-year overall survival. Furthermore, 6.6% of patients survived 2 years without progression, while 1.1% of patients survived 5 years without progression. Two factors that were consistently associated with 2-year and 5-year survival were first-line oncological treatment with standard combined chemoradiotherapy and methylated O6-methylguanine-DNA methyltransferase promoter. Other factors that were significantly associated with 2-year or 5-year survival were age at diagnosis ≤ 60 years, headaches or signs of raised intracranial pressure at diagnosis, cortical contact of contrast enhancement, no contrast enhancement crossing the midline on initial imaging, total or subtotal tumor resection, and a second line of oncological treatment at recurrence. Within 21 cases of 5-year survival, 18 were confirmed to be glioblastomas, IDH-wildtype, and 7 of the 5-year survivors (38.9%) had additional genetic alterations: 3 cases had an FGFR mutation or fusion, 3 cases had a PIK3CA mutation, 1 case had a PTPN11 mutation, and 1 case had a PMS2 mutation in the context of constitutional mismatch repair deficiency syndrome. Conclusions: Five-year overall survival in patients with glioblastoma, IDH-wildtype is extremely low. Predictors of a longer survival are mostly treatment factors, emphasizing the importance of a complete oncological treatment plan, when achievable. Glioblastoma, IDH-wildtype 5-year survivors could be screened for actionable targets in case of recurrence.
Progress Toward Long-Term Survivors of Glioblastoma

J Nathan Cantrell,Mark R Waddle,Maarten Rotman,Jennifer L Peterson,Henry Ruiz-Garcia,Michael G Heckman,Alfredo Quiñones-Hinojosa,Steven S Rosenfeld,Paul D Brown,Daniel M Trifiletti,J. Nathan Cantrell,Mark R. Waddle,Jennifer L. Peterson,Michael G. Heckman,Steven S. Rosenfeld,Paul D. Brown,Daniel M. Trifiletti

DOI: https://doi.org/10.1016/j.mayocp.2018.11.031

IF: 11.104

2019-07-01

Mayo Clinic Proceedings

Abstract:<h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Objective</h3><p>To identify the frequency and characteristics of long-term survivors of glioblastoma.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Patients and Methods</h3><p>Using all cases of glioblastoma with histopathological confirmation in the National Cancer Database from January 1, 2004, through December 31, 2009, clinical, institutional, and treatment-related factors were evaluated with multivariable logistic regression models so as to elucidate factors independently associated with higher than 5-year overall survival after diagnosis.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Results</h3><p>A total of 48,652 patients met the inclusion criteria, with 2249 (4.6%) achieving 5-year survival. Factors associated with odds of improved 5-year overall survival in multivariable analysis were younger age, female sex, less medical comorbidities, nonwhite race, highest median income quartile, left-sided tumors and tumors outside the brainstem, and treatment with radiotherapy (<em>P</em>P=.97).</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Conclusion</h3><p>Despite improvements in median and short-term overall survival shown in recent large clinical trials for glioblastoma, the percentage of patients with glioblastoma achieving 5-year overall survival remains low. This observation calls for the development of practice-redefining therapies and justifies the increased application of radical novel and experimental treatment paradigms for all patients with glioblastoma.</p>

medicine, general & internal
Genome-Wide Analysis of Glioblastoma Patients with Unexpectedly Long Survival.

Timothy E Richardson,Seema Patel,Jonathan Serrano,Adwait Amod Sathe,Elena V Daoud,Dwight Oliver,Elizabeth A Maher,Alejandra Madrigales,Bruce E Mickey,Timothy Taxter,George Jour,Charles L White,Jack M Raisanen,Chao Xing,Matija Snuderl,Kimmo J Hatanpaa

DOI: https://doi.org/10.1093/jnen/nlz025

2019-01-01

Abstract:Glioblastoma (GBM), representing WHO grade IV astrocytoma, is a relatively common primary brain tumor in adults with an exceptionally dismal prognosis. With an incidence rate of over 10 000 cases in the United States annually, the median survival rate ranges from 10-15 months in IDH1/2-wildtype tumors and 24-31 months in IDH1/2-mutant tumors, with further variation depending on factors such as age, MGMT methylation status, and treatment regimen. We present a cohort of 4 patients, aged 37-60 at initial diagnosis, with IDH1-mutant GBMs that were associated with unusually long survival intervals after the initial diagnosis, currently ranging from 90 to 154 months (all still alive). We applied genome-wide profiling with a methylation array (Illumina EPIC Array 850k) and a next-generation sequencing panel to screen for genetic and epigenetic alterations in these tumors. All 4 tumors demonstrated methylation patterns and genomic alterations consistent with GBM. Three out of four cases showed focal amplification of the CCND2 gene or gain of the region on 12p that included CCND2, suggesting that this may be a favorable prognostic factor in GBM. As this study has a limited sample size, further evaluation of patients with similar favorable outcome is warranted to validate these findings.
Clinical characteristics and prognosis of patients with glioblastoma: A review of survival analysis of 1674 patients based on SEER database

Ligang Chen,Jing Ma,Zheng Zou,Hongzhe Liu,Chenxin Liu,Shun Gong,Xu Gao,Guobiao Liang

DOI: https://doi.org/10.1097/md.0000000000032042

IF: 1.6

2022-12-02

Medicine

Abstract:Glioblastoma (GBM) is the most malignant brain tumor, with high morbidity and mortality. [ 1 ] In the United States (US) population, GBM is associated with advanced age and male sex [ 2 ] and is more frequently observed in Caucasians than in other ethnicities. [ 3 ] GBM is disproportionately associated with high morbidity and mortality, with a 5-year overall survival (OS) of only 7.2%, varying by age and sex. [ 4 , 5 ] GBM patients exhibit rapid expansion or destruction of brain structures, accompanied by intertwined nerve symptoms, including focal neurological signs, mental status alterations, and signs of increased intracranial pressure. [ 6 ] Previous studies have shown that risk factors for GBM account for only a small proportion of cases. [ 7 ] Exposure to non-ionizing radiation, mostly due to cell phone usage, is considered a potential risk factor for brain tumors; however, no consistent evidence has been found yet. [ 8 ]

medicine, general & internal
Epid-25. A Seer-Medicare Analysis Of Exposure To Commonly Used Medications And 1-Year Survival In Glioblastoma

Roshani Shah,Patrick Moeller,Scott Keith,Richard Hass,Wenyin Shi,Vittorio Maio,Iyad Alnahhas

DOI: https://doi.org/10.1093/neuonc/noae165.0561

2024-11-29

Neuro-Oncology

Abstract:OBJECTIVESDespite of research efforts, glioblastoma (GBM) remains a deadly disease. We aimed to evaluate the effects of commonly used medications on survival in GBM. METHODSWe performed a retrospective cohort study and utilized the Surveillance, Epidemiology, and End Results (SEER) national cancer registry database linked with Medicare data to identify patients 66 years and older diagnosed with GBM between 1/1/2008 and 12/31/2019. Patients were excluded if they did not receive treatment after diagnosis. We evaluated several medication groups including metformin and oral hypoglycemics, insulin, fluoxetine, statins, beta-blockers, ACE inhibitors and NSAIDs. Mortality was captured within 1 year after diagnosis. Patients were identified as exposed to the medications if they filled at least 1 prescription between 3 months prior to and 9 months after diagnosis. RESULTS9,641 GBM patients were included. 54.4% were male and the mean age was 73.8 ± 5.8 years. As expected, patients 66-70 years of age had the best survival compared to the older age groups. Similarly, patients diagnosed between 2017-2019 had the best survival compared to patients diagnosed in prior years. Moreover, patients with the highest Charlson Comorbidity Index scores had the worst prognosis. Obesity specifically had no effect on survival. Patients who underwent any resection had better survival and patients who received both radiation and chemotherapy had better survival compared to patients who received only one treatment modality. 15.5% of patients were exposed to insulin at 1 year and had worse prognosis (OR 1.65, CI 1.42-1.91). 3.4% of patients were exposed to fluoxetine at one year and surprisingly had worse prognosis (OR 1.35, CI 1.03-1.76). None of the other medication groups had significant effects on survival. CONCLUSIONOur study suggests that exposure to insulin and fluoxetine negatively affects survival in GBM. Stratification of patients per molecular subgroups is necessary for more accurate conclusions.

oncology,clinical neurology
Prognostic Factors of Survival in Glioblastoma Multiforme Patients—A Retrospective Study

Georgiana Șerban,Flaviu Tămaș,Rodica Bălașa,Doina Manu,Corina Tămaș,Adrian Bălașa

DOI: https://doi.org/10.3390/diagnostics12112630

IF: 3.6

2022-10-31

Diagnostics

Abstract:Background: Glioblastoma multiforme (GBM) is the most aggressive brain tumor that occurs in adults. In spite of prompt diagnosis and rapidly administered treatment, the survival expectancy is tremendously poor. Extensive research has been performed in order to establish factors to predict the outcome of GBM patients; however, worldwide accepted prognostic markers are still lacking. Methods: We retrospectively assessed all adult patients who were diagnosed with primary GBM and underwent surgical treatment during a three-year period (January 2017–December 2019) in the Neurosurgery Department of the Emergency Clinical County Hospital of Târgu Mureș, Romania. Our aim was to find any statistically relevant connections between clinical, imagistic, and histopathological characteristics and patients' survival. Results: A total of 75 patients were eventually included in our statistical analysis: 40 males and 35 females, with a median age of 61 years. The mean tumor dimension was 45.28 ± 15.52 mm, while the mean survival rate was 4 ± 6.75 months. A univariate analysis demonstrated a statistically significant impact of tumor size, pre-, and postoperative KPSI on survival rate. In addition, a Cox multivariate assessment strengthened previous findings regarding postoperative KPSI (regression coefficient −0.03, HR 0.97, 95% CI (HR) 0.96–0.99, p = 0.002) as a favorable prognostic factor and GBM size (regression coefficient 0.03, HR 1.03, 95% CI (HR) 1.01–1.05, p = 0.005) as a poor prognostic marker for patients' survival. Conclusions: The results of our retrospective study are consistent with prior scientific results that provide evidence supporting the importance of clinical (quantified by KPSI) and imagistic (particularly tumor dimensions) features as reliable prognostic factors in GBM patients' survival.

medicine, general & internal
Epidemiology of Glioblastoma Multiforme–Literature Review

Szymon Grochans,Anna Maria Cybulska,Donata Simińska,Jan Korbecki,Klaudyna Kojder,Dariusz Chlubek,Irena Baranowska-Bosiacka

DOI: https://doi.org/10.3390/cancers14102412

2022-05-14

Cancers

Abstract:Glioblastoma multiforme (GBM) is one of the most aggressive malignancies, with a median overall survival of approximately 15 months. In this review, we analyze the pathogenesis of GBM, as well as epidemiological data, by age, gender, and tumor location. The data indicate that GBM is the higher-grade primary brain tumor and is significantly more common in men. The risk of being diagnosed with glioma increases with age, and median survival remains low, despite medical advances. In addition, it is difficult to determine clearly how GBM is influenced by stimulants, certain medications (e.g., NSAIDs), cell phone use, and exposure to heavy metals.

oncology
Survival following surgery and prognostic factors for recently diagnosed malignant glioma: data from the Glioma Outcomes Project

Edward R. Laws,Ian F. Parney,Wei Huang,Fred Anderson,Angel M. Morris,Anthony Asher,Kevin O. Lillehei,Mark Bernstein,Henry Brem,Andrew Sloan,Mitchel S. Berger,Susan Chang,_ _

DOI: https://doi.org/10.3171/jns.2003.99.3.0467

IF: 5.408

2003-09-01

Journal of Neurosurgery

Abstract:Object. The Glioma Outcomes Project represents a contemporary analysis of the management of malignant (Grade III and Grade IV/GBM) gliomas in North America. This observational database was used to evaluate the influence of resection, as opposed to biopsy, on patient outcome as measured by the length of survival. Attempts were made to reduce the impact of selection bias by repeating the data analysis after omitting patients with major negative prognostic factors. Methods. Outcome data from 788 patients accrued from multiple sites over a 4-year period (1997–2001) were analyzed with the primary outcome measure being length of survival. Of these, 565 patients with recent diagnoses formed the basis of the present analysis. Patients were systematically followed up until death or up to 24 months after enrollment in the study, and survival data were correlated with the histopathological grade and location of the tumor, the extent of surgery, the patient's performance status, and demographic factors. The median length of survival was 40.9 weeks for patients with recently diagnosed GBMs. The true median length of survival for patients with Grade III gliomas was not reached, although there was a 58% survival rate at 104 weeks. In multivariate analysis, resection rather than biopsy (p < 0.0001), age 60 years or younger (p < 0.0001), and a Karnofsky Performance Scale (KPS) score of 70 or greater (p = 0.0004) were associated with a prolonged survival time for patients with Grade III or IV gliomas. The prognostic value of resection compared with biopsy was maintained (p 60 years, KPS score < 70, or presence of multifocal tumors), who may have been overrepresented in the biopsy group. Survival “tails” at 24 months were 58% for Grade III gliomas and 11% for GBMs. Conclusions. These data provide Class II evidence to support tumor grade, patient's age, and patient's functional status as prognostic factors for survival in individuals with recently diagnosed malignant gliomas. Resection (compared with biopsy) is also a strong prognostic factor; however, no quantitative attempt was made to assess the true extent of the resection.

surgery,clinical neurology
Ten-year survival in glioblastoma. A systematic review

Tomasz Tykocki,Mohamed Eltayeb

DOI: https://doi.org/10.1016/j.jocn.2018.05.002

IF: 2.116

2018-08-01

Journal of Clinical Neuroscience

Abstract:Glioblastoma (GBM) is among the most deadly neoplasms associated with one of the worst 5-year overall survival (OS) rates among all human cancers. The aim of this systematic review is to present all cases with OS of a decade or more and to perform a descriptive analysis of the group. This systematic review was conducted in compliance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline. A comprehensive search for relevant articles was performed on PubMed, Embase and Google Scholar for a period until June 10, 2016, using the following search words: glioblastoma multiforme, glioblastoma, GBM, long-term survival/survivors. Reports containing cases with the long-term survival of 10 years or longer were included in the review. The search produced 36 studies with 162 cases published in the years 1950-2014. The rate of long survivors in the cohort studied was established 0.76%. Mean age at diagnosis, OS and PFS were 31.1 ± 11.1, 15.9 ± 6.3, 11.9 ± 5.6 years respectively. Total and subtotal resections were found in 82 and 58 patients respectively. Nine cases received a biopsy alone. No statistical differences were found in a comparison of PFS, OS and age between total and subtotal resection groups. A regression analysis showed a significant correlation between PFS and OS, with an inverse relationship stated between age at diagnosis and OS. The 10-year survival rate in the cohort studied with GBM was estimated 0.71%. OS was positively correlated with the length of PFS and inversely related with age at diagnosis.

neurosciences,clinical neurology

"Occult" bilingualism in children with school problems.

Prognostication of Survival Outcomes in Patients Diagnosed with Glioblastoma.

Long-term survival of patients with glioblastoma multiforme (GBM)

Epidemiologic Features, Survival, and Prognostic Factors Among Patients With Different Histologic Variants of Glioblastoma: Analysis of a Nationwide Database

Prognosis of glioblastoma patients improves significantly over time interrogating historical controls

EPID-34. GEODEMOGRAPHIC CLASSIFICATION OF GLIOBLASTOMA RISK IN A RURAL HOSPITAL SYSTEM: RELATIONSHIP TO TUMOR INCIDENCE AND OVERALL SURVIVAL

Radt-38. Clinical, Molecular And Imaging Features Associated With Long Term Survival In Glioblastoma Patients

Epid-28. Trends In Low Grade Glioma Prognosis And The Evolving Impact Of Gross Total Resection Across Fifty Years: A Multicohort Analysis

Multiparametric Radiogenomic Model to Predict Survival in Patients with Glioblastoma

Nimg-59. Comparative Analysis Of Long-Term Glioblastoma Survivors Using Machine Learning Generated Radio-Pathomic Metrics

Natural Course and Prognosis of Primary Spinal Glioblastoma: A Nationwide Study

Whole-Genome Multi-omic Study of Survival in Patients with Glioblastoma Multiforme

Long-term survivors in 976 supratentorial glioblastoma, IDH-wildtype patients

Progress Toward Long-Term Survivors of Glioblastoma

Genome-Wide Analysis of Glioblastoma Patients with Unexpectedly Long Survival.

Clinical characteristics and prognosis of patients with glioblastoma: A review of survival analysis of 1674 patients based on SEER database

Epid-25. A Seer-Medicare Analysis Of Exposure To Commonly Used Medications And 1-Year Survival In Glioblastoma

Prognostic Factors of Survival in Glioblastoma Multiforme Patients—A Retrospective Study

Epidemiology of Glioblastoma Multiforme–Literature Review

Survival following surgery and prognostic factors for recently diagnosed malignant glioma: data from the Glioma Outcomes Project

Ten-year survival in glioblastoma. A systematic review